文献速递肝病消化道肿瘤与早癌

监测影像学与甲胎蛋白在肝硬化患者早期肝细胞癌检测中的价值:一项荟萃分析

Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.
PubMed 文献 · Gastroenterology · 2018-02-06

该荟萃分析比较了影像学联合或不联合甲胎蛋白(AFP)在肝硬化患者中早期检测肝细胞癌(HCC)的性能。超声单独检测任何分期HCC的敏感性为84%(95%CI 76%-92%),但早期HCC仅47%(95%CI 33%-61%)。超声联合AFP检测早期HCC的敏感性为63%(95%CI 48%-75%),显著高于超声单独检测的45%(95%CI 30%-62%)(P=.002)。

要点

  • 超声单独检测肝硬化患者早期HCC的敏感性低,仅47%(95%CI 33%-61%)。
  • 超声联合AFP检测早期HCC的敏感性为63%,显著高于超声单独检测的45%(P=.002)。
  • 超声单独检测HCC的特异性高于超声联合AFP(RR 1.08;95%CI 1.05-1.09)。

核心结论

  • 超声单独检测肝硬化患者早期HCC的敏感性低。
  • 在临床实践中,超声联合AFP可显著提高早期HCC检测的敏感性。

研究设计与样本

  • 两位评价者检索了MEDLINE和SCOPUS数据库,时间范围为1990年1月至2016年8月。
  • 纳入报告监测策略检测HCC总体及早期HCC的敏感性和特异性的已发表研究。
  • 采用DerSimonian and Laird随机效应模型计算并比较合并估计值。
  • 研究按照系统评价和荟萃分析优先报告条目(PRISMA)指南进行。
  • 共纳入32项研究,包含13,367例患者。

主要发现

  • 超声检测任何分期HCC的敏感性为84%(95%CI 76%-92%),检测早期HCC的敏感性仅为47%(95%CI 33%-61%)。
  • 在比较超声联合与不联合AFP检测的研究中,超声检测任何分期HCC的敏感性低于超声联合AFP(相对危险度[RR] 0.88;95%CI 0.83-0.93)。
  • 超声检测早期HCC的敏感性低于超声联合AFP(RR 0.81;95%CI 0.71-0.93)。
  • 超声单独检测HCC的特异性高于超声联合AFP(RR 1.08;95%CI 1.05-1.09)。
  • 超声联合AFP与超声单独检测早期HCC的敏感性分别为63%(95%CI 48%-75%)和45%(95%CI 30%-62%)(P=.002)。

关键数值与推荐

  • 超声检测任何分期HCC的敏感性为84%(95%CI 76%-92%)。
  • 超声检测早期HCC的敏感性为47%(95%CI 33%-61%)。
  • 超声联合AFP检测早期HCC的敏感性为63%(95%CI 48%-75%)。
  • 超声单独检测早期HCC的敏感性为45%(95%CI 30%-62%)。
  • 超声单独检测任何分期HCC的敏感性低于超声联合AFP(RR 0.88;95%CI 0.83-0.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Society guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. We compared the performance of surveillance imaging, with or without alpha fetoprotein (AFP), for early detection of HCC in patients with cirrhosis. METHODS: Two reviewers searched MEDLINE and SCOPUS from January 1990 through August 2016 to identify published sensitivity and specificity of surveillance strategies for overall and early detection of HCC. Pooled estimates were calculated and compared using the DerSimonian and Laird method for a random effects model. The study was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. RESULTS: Thirty-two studies (comprising 13,367 patients) characterized sensitivity of imaging with or without AFP measurement for detection of HCC in patients with cirrhosis. Ultrasound detected any stage HCC with 84% sensitivity (95% confidence interval [CI] 76%-92%), but early-stage HCC with only 47% sensitivity (95% CI 33%-61%). In studies comparing ultrasound with vs without AFP measurement, ultrasound detected any stage HCC with a lower level of sensitivity than ultrasound plus AFP measurement (relative risk [RR] 0.88; 95% CI 0.83-0.93) and early-stage HCC with a lower level of sensitivity than ultrasound plus AFP measurement (RR 0.81; 95% CI 0.71-0.93). However, ultrasound alone detected HCC with a higher level of specificity than ultrasound plus AFP measurement (RR 1.08; 95% CI 1.05-1.09). Ultrasound with vs without AFP detected early-stage HCC with 63% sensitivity (95% CI 48%-75%) and 45% sensitivity (95% CI 30%-62%), respectively (P = .002). Only 4 studies evaluated computed tomography or magnetic resonance image-based surveillance, which detected HCC with 84% sensitivity (95% CI 70%-92%). CONCLUSIONS: We found ultrasound alone has a low sensitivity to detect early stage HCC in patients with cirrhosis. Addition of AFP to ultrasound significantly increases sensitivity of early HCC detection in clinical practice.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Tzartzeva K, Obi J, Rich NE, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018. PMID: 29425931. doi:10.1053/j.gastro.2018.01.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。